Single Bout Exercise on Learning in PD
NCT04189887, Completed, National Taiwan University Hospital
Trial 9
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Single Bout Exercise on Learning in PD | ClinicalTrials.gov |
| NCT number | NCT04189887 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Enrollment | 60 participants, actual | ClinicalTrials.gov |
| Lead sponsor | National Taiwan University Hospital | ClinicalTrials.gov |
| Conditions | Parkinson Disease | ClinicalTrials.gov |
| Interventions | aerobic exercise (cycling), Implicit sequence learning | ClinicalTrials.gov |
| First posted | 2019-12-06 | ClinicalTrials.gov |
| Last updated | 2023-03-28 | ClinicalTrials.gov |
Registered outcomes 7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Performance of the sequence learning task | 30 minutes | A serial reaction time task (SRTT) will be used to determine the sequence learning ability. At the beginning of the SRTT, only one circle will be filled with color while others remain hollow. Once the participants hit the correct button, the next target will appear. Unknown to the participants, an 12-element sequence is embedded within the random sequences. The response time of the key presses of the embedded sequence will be recorded. The change score will be calculated between the 1st and 2nd sessions, and between the 1st and 7th sessions. | ClinicalTrials.gov |
| Secondary | Corticomotor excitability | 50 minutes | Transcranial magnetic stimulation (TMS) will be used to evaluate corticomotor excitability. Corticomotor excitability outcomes will include motor evoke potential (MEP), cortical silent period (CSP) duration, short-interval intracortical inhibition (SICI), intracortical facilitation (ICF), and long-interval intracortical inhibition (LICI). The RMT could reflect the membrane excitability of the corticospinal neurons and the cortical interneurons. Peak-to-peak MEP amplitude is an indicator of the integrity and excitability of the corticospinal tract. The CSP is a period when EMG activity being suppressed for a few hundred milliseconds after the MEP, and has often been used as an indicator of the inhibitory mechanism occurs within the corticospinal tract. The SICI, ICF, and LICI have been identified to be good indicators of intracortical inhibition and facilitation. | ClinicalTrials.gov |
| Other | Montreal Cognitive Assessment | 10 minutes | Montreal Cognitive Assessment (MoCA) will be to used to assess general cognitive function of the participants. The total score of MoCA ranges from 0 to 30 and a higher score suggests better cognitive function. The MoCA has good to excellent psychometric properties (sensitivity 90% and specificity 75%), and has been proven as a suitable and accurate standard for screening all levels of cognition for individuals with PD. | ClinicalTrials.gov |
| Other | Stroop test | 5 minutes | Stroop test will be used to assess the ability to inhibit cognitive interference. The participants will be instructed to read out the ink color of the word, but not the color word name, as accurately and as fast as possible within 45 seconds. The more the participants read out correctly, the better they are. | ClinicalTrials.gov |
| Other | The Trail Making test | 5 minutes | The Trail Making Test will be used to assess the ability of visual attention and task switching. Participants will be required to connect alternatively between the numbers and the letters (e.g., 1-rat-2-ox-3-tiger …, etc.) as accurately and as fast as possible. The time taken to finish the test will be recorded and the shorter time suggests better performance. | ClinicalTrials.gov |
| Other | The Unified Parkinson's Disease Rating Scale | 15 minutes | Only the part 3 of the The Unified Parkinson's Disease Rating Scale (UPDRS) will be assessed. It is focus on the motor function. The total score of part 3 ranges from 0 to 72.The higher the score, the more severe the patient is. | ClinicalTrials.gov |
| Other | The New Freezing of Gait Questionnaire | 5 minutes | The New Freezing of Gait Questionnaire (NFOG-Q) will be used to evaluate the freezing frequency and severity of the patients with PD. The total score of NFOG-Q ranges from 0-28.The higher the score, the more severe freezing of gait the patient is suffering from. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 36636767 | DERIVED | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 5
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Serial Reaction Time | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Other outcome | ConductCognition |
| Task Switching Test | Other outcome | ConductCognition |
| Trail Making Test A | Other outcome | ConductCognition |
| Trail Making Test B | Other outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)